Clinical study to confirm the efficacy and safety of SRT(Selective Retina Therapy) in CSC(Central Serous Chorioretinopathy)

A prospective, randomized, comparative clinical trial to evaluate the efficacy and safety of SRT(Selective Retina Therapy) with 'R:GEN' in patients with Central Serous Chorioretinopathy

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0006325

Enrollment

Registered

2021-07-06

Start date

2018-02-13

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : In the case of the treatment group, the assigned SRT(Selective Retina Therapy) treatment was performed. In the case of control group SRT(Selective Retina Therapy) treatment was per

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: In chronic CSC patients, as follows: (1) the eye with persistent ( = 3 months) subretinal fluid (SRF) involving the fovea in the optical coherence tomography (OCT) images of; (2) focal or diffuse active hyperfluorescent leakages due to CSC on the fundus fluorescein angiography (FFA) image; (3) between the age of 19 and 65 years.

Exclusion criteria

Exclusion criteria: (1) the eye with best-corrected visual acuity (BCVA) of 20/200 or worse (Snellen equivalent); (2) other chorioretinal diseases such as choroidal neovascularization (CNV) and polypoidal choroidal vasculopathy (PCV); (3) lens or vitreous opacity interrupting proper retinal imaging and laser treatment; (4) RPE atrophy over 1,000 µm in diameter involving fovea; (5) large PED over 300 µm in width or 100 µm in height; (6) history of conventional laser photocoagulation or PDT for CSC; (7) history of intravitreal injection of anti-VEGF within 10 weeks prior to SRT; (8) Use of systemic, periocular, intraocular corticosteroid within 1 year prior to SRT; (9) use of spironolactone, acetazolamide, or ketoconazole within 2 months prior to SRT.

Design outcomes

Secondary

Measure	Time frame
the change of LogMAR BCVA, CMT, SRF height, and retinal sensitivity on microperimetry were assessed 6 weeks after initial treatment	—

Primary

Measure	Time frame
The complete resolution rate of subretinal fluid on OCT(optical coherence tomography) between the two groups at 6 weeks	—

Countries

Korea, Republic of

Contacts

Public ContactJiyoung Lee

The Catholic University of Korea, Yeouido St. Mary's Hospital

jiyounglee.md@daum.net+82-2-3779-1848

Outcome results